Stockscreener 앱 받기
4.22
11.94%
0.45
Climb Bio Inc 주식(CLYM)의 최신 뉴스
ImmunityBio shares climb as bladder cancer trial nears full enrollment, BLA submission expected by year end - Seeking Alpha
ImmunityBio shares climb 3% premarket after company's prelim quarterly revenue exceeds estimates - marketscreener.com
Resistance Check: How Climb Bio Inc stock benefits from tech adoption2025 Bull vs Bear & Long-Term Growth Portfolio Plans - Bộ Nội Vụ
Patterns Watch: How Climb Bio Inc stock benefits from tech adoption2025 Trading Volume Trends & Weekly Hot Stock Watchlists - Bộ Nội Vụ
Winners Losers: Is Climb Bio Inc stock positioned well for digital economyJuly 2025 PostEarnings & Daily Profit Maximizing Trade Tips - Bộ Nội Vụ
Bull Bear: Is Climb Bio Inc stock positioned well for digital economyJuly 2025 Chart Watch & High Conviction Buy Zone Picks - Bộ Nội Vụ
Laser Focus WorldClimb Bio to Present at Upcoming September 2025 Investor Conferences - FinancialContent
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Update Report: Why analysts upgrade Climb Bio Inc stockJuly 2025 Review & Real-Time Buy Signal Notifications - moha.gov.vn
Can Climb Bio Inc. stock deliver sustainable ROEMarket Trend Review & Weekly Top Gainers Trade List - Улправда
Climb Bio advances clinical trials with first patients dosed in key studies - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM) and Halozyme (HALO) - The Globe and Mail
Climb Bio’s CLYM116 Moves Into First-in-Human Testing: What Early Investors Should Watch - TipRanks
Climb Bio initiated with a buy at Freedom Capital - MSN
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 - Sahm
Is Climb Bio Inc. stock oversold or undervaluedProfit Target & Low Risk High Reward Ideas - Улправда
Analyst Downgrade: Can Climb Bio Inc. stock maintain growth trajectoryJuly 2025 Summary & Low Risk Growth Stock Ideas - Улправда
How Climb Bio Inc. stock reacts to oil pricesTreasury Yields & Free Weekly Watchlist of Top Performers - Улправда
Climb Bio outlines 2026 clinical milestones and cash runway - TipRanks
Climb Bio advances clinical trials with first patients dosed in key studies By Investing.com - Investing.com South Africa
Pasadena Star-News: Local News, Sports, Things to DoClimb Bio, Inc.Common Stock (Nasdaq:CLYM) Stock Quote - FinancialContent
Climb Bio reports inducement grant under Nasdaq listing rule - MSN
Climb Bio, Inc.Common Stock (NQ: CLYM - markets.financialcontent.com
Climb Bio (NASDAQ:CLYM) Director Purchases $24,888.50 in Stock - MarketBeat
Climb Bio (CLYM) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Climb Bio Inc Stock Analysis and ForecastSector Performance Review & Explosive Capital Growth Plans - Early Times
Setup Watch: Will SBUX stock benefit from commodity pricesPortfolio Value Summary & AI Driven Price Forecasts - moha.gov.vn
Alumis issues breach notice to Climb Bio over $3 million milestone payment - Investing.com Nigeria
Climb Bio appoints Edgar D. Charles as Chief Medical Officer - MSN
Alumis IncCo & Its Unit Issues Notice Of Material Breach & Notification Of Claim For Indemnification To Climb BioSEC Filing - TradingView — Track All Markets
Alumis issues breach notice to Climb Bio over $3 million milestone payment By Investing.com - Investing.com South Africa
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Alumis Faces Legal Dispute Over Unpaid Budoprutug Milestone - TipRanks
Climb Bio challenges Alumis milestone and royalty obligations - MSN
HC Wainwright forecasts 2026 data readouts for Climb Bio’s (CLYM) Budoprutug across clinical tracks - MSN
Climb Bio files complaint against Alumis and AcelyrinSEC filing - MarketScreener
Climb Bio Challenges Alumis Milestone and Royalty Obligations - TipRanks
Climb Bio, Inc. Files Legal Complaint Over Asset Purchase Agreement - TradingView — Track All Markets
H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical Tracks - Insider Monkey
Freedom Capital Markets initiates Buy rating on Climb Bio stock with $9 target - Investing.com Canada
Climb Bio initiated with a Buy at Freedom Capital - TipRanks
Apollo Tyres Limited Stock Poised for Technical ComebackTrading Psychology Tips & Outstanding Investment Portfolio - bollywoodhelpline.com
10 Best Biotech Penny Stocks to Buy According to Analysts - Insider Monkey
Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation - Yahoo Finance
Climb Bio price target raised to $11 from $9 at HC Wainwright - MSN
Retail investors in Climb Bio, Inc. (NASDAQ:CLYM) are its biggest bettors, and their bets paid off as stock gained 15% last week - simplywall.st
Vilin Bio Med Limited Breaks Losing Streak — Is the Trend ReversingStock Split Announcements & Rapid Wealth Accumulation - bollywoodhelpline.com
AI Indicators Detect Buy Opportunity in Shree OSFM ESupport and Resistance Levels & Build a Smarter Portfolio Right Now - bollywoodhelpline.com
Candlestick Signal Suggests Reversal in Rajputana Industries LimitedTechnical Resistance Breaks & Accelerated Capital Growth - bollywoodhelpline.com
HC Wainwright Reduces Earnings Estimates for Climb Bio - MarketBeat
Climb Bio Earnings Notes - Trefis
Climb Bio Inc. (CLYM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why analysts upgrade Climb Bio Inc. stockMarket Sentiment Report & Technical Pattern Based Buy Signals - DonanımHaber
Climb Bio, Inc. (NASDAQ:CLYM) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
H.C. Wainwright raises Climb Bio stock price target to $11 on budoprutug progress - Investing.com Canada
Pre Market Movers: ALGS, PDSB, PCSA Swing Big - RTTNews
4.73%
0.92%
자본화:
|
볼륨(24시간):